SecBot SecBot
8-K ·Filed Feb 26, 2026

NVAX

NOVAVAX INC
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001000694-26-000011
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The Pfizer partnership validates Novavax's Matrix-M technology and provides significant future revenue potential. Traders should monitor milestone achievements and royalty streams. The strong revenue growth and improved profitability suggest a turnaround, but the decline in Nuvaxovid sales and cash balance warrant caution. The $330 million credit facility strengthens the balance sheet for future R&D investments.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.19
T+0 close · Feb 26, 2026 · via day close
Latest settled
−19.75%
T+60 · $8.98
Vs SPY
−27.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $11.19entry
  2. T+1 · 9mo ago −9.38%α −8.93% · $10.14
  3. T+5 · 9mo ago −10.72%α −9.60% · $9.99
  4. T+20 · 8mo ago −20.02%α −13.62% · $8.95
  5. T+60 · 6mo ago −19.75%α −27.50% · $8.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $1.12 billion for the full year, driven by Sanofi milestones and licensing revenue. The company also announced a major non-exclusive license agreement with Pfizer for its Matrix-M adjuvant technology, receiving a $30 million upfront payment and potential for up to $500 million in milestones. Despite a cash balance decline to $751 million, Novavax secured a $330 million credit facility and guided to $230-$270 million in adjusted revenue for 2026.

Key Financial Metrics

Revenue
$147.1M
+67.0% YoY
EPS
$0.11
Guidance
$230M-$270M
initiated

Key Facts

  • Q4 2025 revenue: $147 million (+67% YoY)
  • Full year 2025 revenue: $1.123 billion (+65% YoY)
  • Net income: $18 million in Q4 2025 vs. $81 million loss in Q4 2024
  • Pfizer agreement: $30 million upfront, up to $500 million in milestones, and high-mid-single digit royalties
  • Sanofi partnership: $225 million in milestones earned in 2025
  • Cash balance: $751 million as of Dec 31, 2025
  • 2026 revenue guidance: $230-$270 million (adjusted total revenue)

Financial Impact

Revenue increased by $589 million YoY to $1.123 billion in 2025, with Q4 revenue up $59 million to $147 million. Net income improved by $99 million YoY in Q4.

revenuenet incomecash flowguidance

Segment Breakdown

SegmentRevenueGrowth
Nuvaxovid Sales$625.0MNot reported
Sanofi$386.0M-16.0%
Licensing, Royalties and Other Revenue$438.4M-7.0%

Risk Factors

  • Decline in Nuvaxovid product sales from $625 million in 2025 to $35-$45 million expected in 2026
  • Cash balance decreased from $938 million in 2024 to $751 million in 2025
  • Future revenue dependent on partner performance (Sanofi, Pfizer) and milestone achievement

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001000694-26-000011
Document: nvax-20260226.htm0001000694-26-000011
Document: 0001000694-26-000011-index-headers.html0001000694-26-000011
Document: 0001000694-26-000011-index.html0001000694-26-000011
Document: 0001000694-26-000011.txt0001000694-26-000011

Track record

9 reports on NVAX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
  3. Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
  4. Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
  5. Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
  6. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
  7. May 6, 202627w ago 8-K Neutral 4/10 Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
  8. Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Viewing Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026